CMV seropositivity is associated with increased microbial translocation in people living with HIV and uninfected controls.
Cytomegalovirus (CMV) seropositivity and anti-CMV IgG levels are associated with adverse health outcomes in elderly populations. Among people living with HIV (PLWH) CMV seropositivity has been associated with persistent CD8 T-cell elevation and increased risk of developing non-AIDS comorbidities despite long-term antiretroviral therapy (ART). Herein, we investigated whether CMV seropositivity and elevation of anti-CMV IgG levels were associated with increased epithelial gut damage, microbial translocation, and systemic inflammation. A total of 150 PLWH (79 ART-naïve and 71 ART-treated) were compared to 26 HIV-uninfected controls (UC). Plasma markers of HIV disease progression, epithelial gut damage, microbial translocation, non-specific B cell activation, anti-CMV and anti-EBV IgG levels, and pro-inflammatory cytokines were measured. CMV seropositivity and elevated anti-CMV IgG levels were associated with markers of epithelial gut damage, microbial translocation, and inflammation in PLWH and HIV-uninfected participants. In contrast, total non-specific IgG, IgM, IgA, and anti-EBV IgG levels were not associated with these markers. CMV seropositivity was associated with markers of epithelial gut damage, microbial translocation, and inflammation independently of sociodemographic and behavioural characteristics of the study population. CMV-seropositive people with and without HIV had increased epithelial gut damage, microbial translocation, and inflammation. Furthermore, anti-CMV IgG levels were independently associated with increased epithelial gut damage and microbial translocation. CMV co-infection may partially explain persistent gut damage, microbial translocation, and inflammation in ART-treated PLWH.